PER 1.41% 7.0¢ percheron therapeutics limited

UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-30

  1. 13,147 Posts.
    lightbulb Created with Sketch. 1380
    my Dd tells me that the Morgan’s conference also caters for small Biotech’s seed capital
    Akki: once again you create a false hidden agenda
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.